First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System

Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures

MARLBOROUGH, Mass., Jan. 16, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025.

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease

MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease.

MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst.

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases

MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. Food and Drug Administration. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer.

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation

MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-breaking science session at the American Heart Association's Scientific Sessions 2024, and simultaneously published in The New England Journal of Medicine.

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

"Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisition, we're pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity."

MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.

Nick Spadea-Anello, president, Electrophysiology, and Jon Monson, senior vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at approximately 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation

MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.1 

MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).

MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.